^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
M802
i
Other names: M802, M 802
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
YZY Biopharma
Drug class:
CD3 agonist, HER2 antagonist
Related drugs:
over3years
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=32, Not yet recruiting, Wuhan YZY Biopharma Co., Ltd. | Trial completion date: Mar 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Nov 2023
Clinical • Trial completion date • Trial primary completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
|
HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression
|
M802
over4years
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=32, Recruiting, Wuhan YZY Biopharma Co., Ltd.
Clinical • New P1 trial
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
|
HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression
|
M802
Share via
